The differences observed in the mutation rates of WNT/APC/β-catenin pathway components in the two groups differing in SOX2 expression was in a significant degree due to the high mutation rate in MSI-high cancers, which were more prevalent in cancers with suppressed SOX2 mRNA expression. The gene discussed is SOX2; the disease is cancer.